PDSBPDS BiotechnologyPDSB info
$3.07info-1.60%24h
Global rank21493
Market cap$95.50M
Change 7d-9.71%
YTD Performance-38.23%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    PDS Biotechnology (PDSB) Stock Overview

    PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. The company is developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

    PDSB Stock Information

    Symbol
    PDSB
    Address
    25B Vreeland RoadFlorham Park, NJ 07932United States
    Founded
    -
    Trading hours
    -
    Website
    https://www.pdsbiotech.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    800 208 3343

    PDS Biotechnology (PDSB) Price Chart

    -
    Value:-

    PDS Biotechnology Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $3.07
    N/A
    Market Cap
    $95.50M
    N/A
    Shares Outstanding
    31.11M
    N/A
    Employees
    26.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org